What question did this study set out to answer?

The research aims to evaluate the effectiveness of elisrasib in patients with KRAS G12C-mutant non-small cell lung cancer.

April 23, 2026

Elisrasib Elicits Clinical Benefit in KRASG12C-mutant NSCLC

Key Points

The research aims to evaluate the effectiveness of elisrasib in patients with KRAS G12C-mutant non-small cell lung cancer.
Phase I/II clinical trial
Patients with locally advanced or metastatic KRAS G12C-mutant NSCLC treated with elisrasib
Assessment of clinical responses and disease control rates
98.5% disease control rate in KRAS G12C inhibitor-naïve patients
83.9% disease control rate in patients refractory to other KRAS inhibitors
Demonstrated robust and durable clinical responses

Abstract

In a phase I/II clinical trial, patients with locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer treated with the next-generation KRASG12C inhibitor elisrasib showed robust and durable clinical responses. Patients naïve to KRASG12C inhibitors, as well as those refractory to other such drugs, experienced high rates of disease control-98.5% and 83.9%, respectively.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Journals

Cancer Discovery

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Elisrasib Elicits Clinical Benefit in KRASG12C-mutant NSCLC

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Journals

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study